Drugs / Terameprocol
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT02575794 | May 2018 → Sep 2023 | glioma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 1 | NCT00664677 | Aug 2007 → Mar 2009 | acute myeloid leukemia, adult T-cell leukemia/lymphoma, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, chronic lymphocytic leukemia/small lymphocytic lymphoma +2 | Erimos Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT00664586 | May 2007 → Apr 2009 | lymphoma | Erimos Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT00259818 | Dec 2005 → Jan 2008 | cancer | Erimos Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00154089 | Nov 2004 → Apr 2006 | cervical intraepithelial neoplasia | Erimos Pharmaceuticals | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT00404248 Comparator | Jan 2007 → Jun 2009 | central nervous system neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2004-08-09 | Erimos Pharmaceuticals | Results Erimos Pharmaceuticals Presents Positive Safety and Preliminary Efficacy Results from a Phase I Clinical Trial of EM-1421 in Refractory Cancer Patients at the 6th International Conference on Head and Neck Cancer erimos.com ↗
The study showed that EM-1421-IT administered at 20mg/cm3 up to a maximum total administered dose of 1485mg appears to be tolerable and not associated with systemic side effects. |
All press releases naming this drug 3 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Terameprocol | “Terameprocol” NCT00664586 ↗ |
| Known as | EM-1421 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00259818 ↗ |
| Action | Inhibit | “a transcriptional inhibitor of specificity protein 1 (Sp1)-regulated proteins” PMID 38955178 ↗ Jul 2024 |
| Modality | Small molecule | — CHEMBL90983 ↗ |
| Route | Other | “EM-1421 administered intravaginally every 3 weeks as 45 mg (1% w/w) EM-1421 or 90 mg (2% w/w) EM-1421” NCT00154089 ↗ |